GLP-1 Drug Market
Latest in GLP-1 Drug Market· Nov 11
Ro's revenue jumped tenfold after shifting its telehealth platform to prioritize GLP-1 weight-loss and diabetes drugs over primary care services. The company reorganized internally to capitalize on high margins in pharmaceutical distribution rather than traditional doctor visits, exemplifying how digital health operators are abandoning lower-margin primary care to compete in the obesity and diabetes drug market. This repositioning reflects the structural pull of GLP-1 demand reshaping telehealth business models across the sector.
How GLP-1 weight-loss and diabetes drugs are reshaping demand, pricing and competition across pharma, food and consumer markets.
15 events tracked
- Single source1 day ago
Ro's revenue surges tenfold after embracing GLP-1 weight-loss drugs
Ro, a telehealth platform, revived its business through GLP-1 drug offerings and operational restructuring.
The New York Times
- Single source3 days ago
Novonesis pursues gut-health supplements for obesity medication users
Supplement makers see market opening as GLP-1 drugs reshape weight-loss category.
CNBC
- Reported by 2 outlets8 days ago
Novo lifts annual forecast on Wegovy pill sales surge
Novo Nordisk raises 2024 guidance on stronger-than-expected oral Wegovy sales.
MarketWatch · CNBC
- Single source14 days ago
Analyst lifts Eli Lilly price target on obesity drug momentum
CNBC raises Eli Lilly price target on sustained obesity-drug demand.
CNBC
- Single source14 days ago
Eli Lilly raises full-year guidance as Zepbound, Mounjaro sales accelerate
Eli Lilly beats earnings estimates and raises full-year sales guidance, citing strong demand for obesity drugs Zepbound and Mounjaro.
CNBC
- Single source15 days ago
Traders wager against Chipotle ahead of earnings report
Traders are placing large bearish bets on a restaurant company ahead of earnings.
CNBC
- Single source16 days ago
Employers drop GLP-1 weight-loss coverage as premiums climb
Employer health plans are dropping GLP-1 drug coverage ahead of 2027, narrowing weight-loss options for workers.
CNBC
- Single source17 days ago
Cramer: Tech insiders recommend biotech stock over AI plays
Cramer reports tech insiders recommend a drug stock as a buy, citing unnamed sources.
CNBC
- Single source20 days ago
Weight-loss drugs threaten beer sales, major brewer tells UK bars
Heineken warns UK pubs that weight-loss drug adoption will reduce beer consumption and pub visits.
The Guardian
- Single source21 days ago
L'Oreal CEO cites weight loss drugs as drag on beauty sales
L'Oreal reports weight loss drugs are damaging beauty and skincare sales.
BBC News
- Single source29 days ago
South Australia's inaugural Michelin-starred restaurants number eleven establishments
Michelin Guide awards inaugural stars to 11 Australian restaurants, signaling prestige dining market expansion in the region.
BBC News
- Single source30 days ago
Walmart expands worker benefits to include free diabetes and respiratory medications
Walmart expands employee benefits to cover GLP-1 drugs, inhalers, and insulin at no cost.
CNBC
- Single sourceabout 1 month ago
Butter experiences cultural resurgence as specialty shops and collectors embrace the dairy product
Global butter demand has surged, reversing a long decline in consumption of the dairy product.
The Guardian
- Single sourceabout 1 month ago
Appetite-suppressing medications weigh on restaurant sales and traffic
Weight loss drugs reduce diner appetite, pressuring restaurant traffic and spending.
The New York Times
- Single sourceabout 1 month ago
Novo Nordisk's oral obesity drug proves effective for patients transitioning from injections
Novo Nordisk's Wegovy oral formulation maintains weight-loss efficacy in real-world patients switching from injectable GLP-1 drugs.
CNBC